➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Moodys
Medtronic
Merck
Express Scripts
McKinsey

Last Updated: January 18, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Eleclazine

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Eleclazine?

Eleclazine is an investigational drug.

There have been 6 clinical trials for Eleclazine. The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2014.

The most common disease conditions in clinical trials are Long QT Syndrome, Syndrome, and Cardiomyopathy, Hypertrophic. The leading clinical trial sponsors are Gilead Sciences and [disabled in preview].

There are eight US patents protecting this investigational drug and one hundred and forty-two international patents.

Recent Clinical Trials for Eleclazine
TitleSponsorPhase
Effect of Eleclazine on QT, Safety, and Tolerability in Adults With Long QT2 SyndromeGilead SciencesPhase 1
Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Renal FunctionGilead SciencesPhase 1
Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Hepatic FunctionGilead SciencesPhase 1

See all Eleclazine clinical trials

Clinical Trial Summary for Eleclazine

Top disease conditions for Eleclazine
Top clinical trial sponsors for Eleclazine

See all Eleclazine clinical trials

US Patents for Eleclazine

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Eleclazine   Start Trial Fused heterocyclic compounds as ion channel modulators Gilead Sciences, Inc. (Foster City, CA)   Start Trial
Eleclazine   Start Trial Fused heterocyclic compounds as ion channel modulators Gilead Sciences, Inc. (Foster City, CA)   Start Trial
Eleclazine   Start Trial Methods of treating hypertrophic cardiomyopathy Gilead Sciences, Inc. (Foster City, CA)   Start Trial
Eleclazine   Start Trial Compound and methods for treating long QT syndrome Gilead Sciences, Inc. (Foster City, CA)   Start Trial
Eleclazine   Start Trial Fused heterocyclic compounds as ion channel modulators Gilead Sciences, Inc. (Foster City, CA)   Start Trial
Eleclazine   Start Trial Solid forms of an ion channel modulator Gilead Sciences, Inc. (Foster City, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Eleclazine

Drugname Country Document Number Estimated Expiration Related US Patent
Eleclazine Argentina AR086828 2031-07-01   Start Trial
Eleclazine Argentina AR086829 2031-07-01   Start Trial
Eleclazine Australia AU2012279214 2031-07-01   Start Trial
Eleclazine Australia AU2012279236 2031-07-01   Start Trial
Eleclazine Australia AU2013201608 2031-07-01   Start Trial
Eleclazine Brazil BR112013032027 2031-07-01   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Moodys
Medtronic
Merck
Express Scripts
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.